BIO-key International, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BKYI research report →
Price Chart
About the company
BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions in the United States and internationally. It offers BIO-key PortalGuard and PortalGuard IDaaS cloud-based identity platforms, which allows authentication through an IAM platform; and BIO-key VST and WEB-key; civil and large-scale ID infrastructure.
- CEO
- Michael W. DePasquale
- IPO
- 1997
- Employees
- 42
- HQ
- Holmdel, NJ, US
Get TickerSpark's AI analysis on BKYI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.07M
- P/E
- -0.32
- Fwd P/E
- 9.09
- PEG
- 0.01
- P/S
- 0.63
- P/B
- 0.43
- EV/EBITDA
- -0.76
- Div Yield
- 0.00%
- Gross Margin
- 84.73%
- Op Margin
- -46.40%
- Net Margin
- -49.92%
- ROE
- -52.19%
- ROIC
- -46.44%
Latest fiscal year · YoY change
- Revenue
- $5.94M-14.3%
- Gross Profit
- $4.56M-19.1%
- Op Income
- $-6,827,607
- Net Income
- $-7,157,946-66.4%
- EPS
- $-10.77+48.4%
- OCF Growth
- -60.0%
- FCF Growth
- -59.7%
- 52W High
- $9.00
- 52W Low
- $1.55
- 50D MA
- $2.40
- 200D MA
- $4.28
- Beta
- 0.40
- RSI (14)
- 44
- Avg Volume
- 5.45M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BIO-key delivered 39% license growth and 90% gross margin in Q3, while weaker hardware sales kept total revenue slightly down and management highlighted a stronger pipeline heading into Q4 and 2027.· November 13, 2026
- License fee revenue grew 39% year over year to $1.28 million and made up 86% of total revenue.
- Total Q3 revenue was $1.48 million, down 4% from $1.55 million a year ago because hardware revenue fell sharply.
- Gross margin improved to 90% from 77% last year, with management saying margin has improved every quarter since Q2 2025.
- The company retired its remaining note payable, ended the quarter effectively debt-free, and had $2.2 million of cash plus $3.1 million of working capital.
- Management pointed to large international wins in the Middle East and Europe, plus a new U.S. casino win and an agentic AI authentication opportunity.
Q3 2026 total revenue was $1.48 million, compared with $1.55 million in Q3 2025. License fee revenue increased 39% to $1.28 million; hardware revenue was $12,000 versus $364,000 a year ago; and sales, maintenance, and other revenue fell 27% to $195,000. Gross profit rose 12% to $1.34 million and gross margin improved to 90% from 77% in Q3 2025. Operating expenses increased 4% year over year, operating loss improved to $820,000 from $892,000, and net loss improved to $886,000 from $965,000, though net loss available to common stockholders was $5.9 million due to a $4.5 million non-cash deemed dividend tied to the August warrant inducement. For the first nine months, revenue increased 14% to $5.55 million and net loss improved 42% to $1.67 million. Management said the larger international hardware order was pushed out, but expects to continue selling it through year-end and into early next year; it also expects roughly $1.2 million in annual license fee renewals in Q1 alone and is targeting profitability around that timeframe.
Mike DePasquale said the quarter showed the strength of BIO-key’s core software model, with recurring license revenue and a higher mix of software lifting margins and reducing losses. He emphasized that the company is seeing traction in regulated markets such as government, defense, and banking, especially in the Middle East and Europe, where it is winning larger deals and building partner-led distribution. He also framed agentic AI authentication as a meaningful new opportunity and called the company’s international pipeline, cash position, and cleaner balance sheet a foundation for a stronger 2027.
Ceci Welch said Q3 revenue was $1.48 million, with $1.28 million of license revenue, $12,000 of hardware revenue, and $195,000 of sales, maintenance, and other revenue. She highlighted gross profit of $1.34 million and gross margin of 90%, up from 77% last year, and noted operating loss improved to $820,000. On the balance sheet, she said stockholders’ equity rose to $6.5 million, current assets were $5.3 million including $2.2 million of cash and $2.4 million of accounts receivable, and working capital improved to $3.1 million. She also said the company retired its remaining note payable, leaving only a small euro loan of about EUR 12,000, and raised $2.5 million of gross proceeds from the August warrant inducement.
Analysts focused on the lagging hardware revenue, rising accounts receivable, and whether the company was still on track for profitability. Management said the hardware order was not lost but delayed and being shipped in smaller tranches, while the AR increase reflected new customer wins in the Middle East and could support cash flow if collections come in as expected. They also said the U.S. casino win is a single-entity, three-year six-figure deal that could open more gaming opportunities, and described agentic AI authentication as a 'killer app' that can work alongside existing identity platforms. When asked about profitability timing, management said it expects a strong Q4, is targeting profitability and cash flow positivity, and expects a significant fourth quarter above prior years’ Q4 revenue levels.
The bull case is that BIO-key is transitioning toward a higher-margin, recurring software model, with license revenue up 39% and gross margin at 90%. Management described a robust pipeline in regulated sectors, multiple new Middle East customers, and a new U.S. casino win that could expand the domestic channel opportunity. They also believe the balance sheet is strong enough to fund operations without raising capital.
The main risks discussed were the timing of large hardware deployments, which can slip across quarters, and collections tied to partner-led sales, which can keep accounts receivable elevated. Total Q3 revenue still declined 4% year over year, and U.S. business was described as relatively flat compared with more active international markets. Management also acknowledged that profitability timing has shifted and remains dependent on closing and collecting larger deals.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.9%
- Shares Outstanding
- 2.04M
- Float Shares
- 1.91M
of shares held by institutions
4 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | DEPASQUALE MICHAEL W | buy | 1,986 |
| Jun 30, 26 | Sullivan James David | other | 250 |
| Jun 30, 26 | DEPASQUALE MICHAEL W | other | 250 |
| Jun 30, 26 | LACOUS MIRA K | other | 250 |
| Dec 31, 25 | LACOUS MIRA K | other | 2,500 |
| Dec 31, 25 | Sullivan James David | other | 2,500 |
| Dec 31, 25 | DEPASQUALE MICHAEL W | other | 2,500 |
| Sep 16, 25 | DEPASQUALE MICHAEL W | buy | 1,617 |
| Sep 15, 25 | DEPASQUALE MICHAEL W | buy | 2,500 |
| Sep 16, 25 | DEPASQUALE MICHAEL W | buy | 1,617 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BKYI coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BKYI?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
BIO-key: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 16
BIO-key International, Inc. (BKYI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
BIO-key International Inc. (BKYI) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 13
BIO-key Q3 Software License Fees Grew 39%, Its Third Consecutive Quarter of Double-Digit Growth, Driven Primarily by Momentum in the Middle East and Europe; Hosts Call Today at 10am ET
globenewswire.com · Nov 13
BIO-key Enters Gaming / Hospitality Market with Contract from Major U.S. Casino Resort
globenewswire.com · Nov 11
Identity and Biometric Authentication Technologies Provider BIO-key Hosts Q3 Investor Call Friday, November 13 at 10am ET
globenewswire.com · Nov 6
Identity and Biometric Authentication Technologies Provider BIO-key Hosts Q3 Investor Call Friday, November 13 at 10am ET
globenewswire.com · Nov 6
Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
